Tango Therapeutics Inc Asset Resilience Ratio
Tango Therapeutics Inc asset resilience ratio. Tango Therapeutics Inc (TNGX) has an Asset Resilience Ratio of 62.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Tango Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tango Therapeutics Inc (2019–2025)
Asset resilience ratio of Tango Therapeutics Inc from 2019 to 2025. This chart shows how Tango Therapeutics Inc's Asset Resilience Ratio has changed over time. See cash generation quality of Tango Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Tango Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Tango Therapeutics Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $668.43 Million | 62.24% |
| Total Liquid Assets | $668.43 Million | 62.24% |
Asset Resilience Insights
- Very High Liquidity: Tango Therapeutics Inc maintains exceptional liquid asset reserves at 62.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tango Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tango Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Tango Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Tango Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Tango Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.90% | $230.86 Million | $398.69 Million | -1.62pp |
| 2024-12-31 | 59.52% | $188.39 Million | $316.49 Million | -7.67pp |
| 2023-12-31 | 67.19% | $270.50 Million | $402.57 Million | -2.95pp |
| 2022-12-31 | 70.15% | $306.17 Million | $436.47 Million | +1.66pp |
| 2021-12-31 | 68.48% | $342.51 Million | $500.15 Million | -9.66pp |
| 2020-12-31 | 78.14% | $161.94 Million | $207.25 Million | +46.69pp |
| 2019-12-31 | 31.45% | $17.54 Million | $55.76 Million | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more